DTTBI RPI

The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Information (RPI) focused on Drug Treatment for Traumatic Brain Injury (DTTBI) - to rapidly advance the development of TBI drug candidate prototypes, through focused Phase 2 clinical trial testing, to produce a TBI drug that has been fully characterized and ready for Phase 3 trial. The end goal of DTTBI is a commercial TBI drug product that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate - severe TBI. This RPI contains background material and guidance for the preparation of Project Information Papers to MTEC. Project Information Papers will be reviewed by the Sponsor and used in a manner that shapes a future MTEC solicitation that requests full project proposals (RPP). The results of the Project Information Paper submissions will serve as a means to assess the TBI drug development clinical landscape, identify assumptions, scope of the project, and clarify the proposal effort that will follow. See the attachment for the details of this RPI Project information papers are due no later than December 11, 2017 at noon Eastern Time. This RPI will be posted to the MTEC website ( www.mtec-sc.org ). MTEC membership is NOT required for the submission of a Project Information Paper in response to this MTEC RPI. To view this RPI, please visit https://mtec-sc.org/active-solicitations/